Company: ZVRA
Filing Date: 2025-04-29
Form Type: DEFC14A
Source: 0000897069-25-000885
Chunk: 16

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-29
Form: DEFC14A
Chunk 16
---
 term will expire at the 2028 annual meeting of stockholders; Class II, whose current term will expire at the 2026 annual meeting of stockholders; and Class III, whose term will expire at the 2027 annual meeting of stockholders. The current Class I directors are Wendy Dixon, PhD and Tamara A. Favorito; the current Class II directors are John B. Bode, Douglas W. Calder, and Corey Watton; and the current Class III directors are Thomas D. Anderson, Neil F. McFarlane and Alvin Shih, M.D. Mr. Mangless is seeking your proxy to vote for the election to the Board of Directors of two highly qualified nominees - Travis C. Mickle, PhD and Arthur C. Regan.If elected as a director of the Company, Mr. Regan would be, an “independent director” within the meaning of (i) applicable Nasdaq listing standards applicable to board composition and (ii) Section 301 of the Sarbanes-Oxley Act of 2002. If elected as a director of the of the Company, Dr. Mickle would not qualify as an “independent director” within the above meaning by virtue of his having been an employee of the Company within the last three years. The Proponent is not seeking to acquire control of the Company. However, if elected, the Nominees, together with the Proponent’s three nominees who were elected at the 2023 annual meeting, will constitute a majority on the Board and will potentially be able to implement any actions that they may believe are necessary to unlock stockholder value. That said none of the Nominees nor any of the prior three nominees is a party to any agreement, arrangement or understanding with, and none has given any commitment or assurance to each other or any other person as to how she or he, will act or vote on any issue or question. Each such person will fulfill its fiduciary duty in determining how to vote on any issue that comes before the Board of Directors. The Proponent’s sole interest is in electing a board with the qualifications and ability to facilitate necessary and meaningful changes in order to maximize long-term value for the Company’s stockholders. Biographical Information Regarding the Nominees The following information concerning the age, principal occupation and business experience during the last five years, and current public directorships of each of the Nominees. Travis C. Mickle, PhD, 52, currently serves as a Senior Advisor and Consultant,